Amyloid pathology related to aberrant structure-function coupling of brain networks in Alzheimer's disease: insights from [18F]-florbetapir PET imaging
Related Experiment Video
Updated: Jun 14, 2025

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451
Published on: April 18, 2025
Hao-Jie Chen1,2,3, Mingkai Zhang4, Min Wei4
1State Key Laboratory of Cognitive Neuroscience and Learning & IDG, McGovern Institute for Brain Research, Beijing Normal University, Beijing, 100875, China.
Purpose:
Brain structure-function coupling (SFC), which reflects the degree to which anatomical structure supports neural function, is an emerging imaging marker in neurodegenerative diseases. However, its pathological underpinnings in Alzheimer's disease (AD) remain poorly understood. This study aimed to examine the association among amyloid pathology, SFC disruption and cognitive decline.
Methods:
We included 173 participants from the SILCODE cohort, comprising cognitively unimpaired (CU) and cognitively impaired (CI) individuals. Amyloid pathology was quantified using [18F]-florbetapir PET standardized uptake value ratios (SUVR). Structural connectivity (SC) was derived from diffusion-weighted MRI with probabilistic tractography, while functional connectivity (FC) was calculated from resting-state functional MRI. SFC was defined as the coefficient of determination from linear models predicting FC based on SC at regional level. Linear regression and mediation analyses were conducted to assess relationships between amyloid pathology, SFC, and multiple cognitive performances.
Results:
Compared to CU individuals, CI participants exhibited increased regional SFC primarily within the default mode network regions (p < 0.05). In CI participants, amyloid pathology correlated with SFC across occipital lobe, precuneus and temporoparietal regions, which was specific by APOE ε4 status (p < 0.05). Mediation analyses revealed that SFC partially mediated the relationship between amyloid pathology and cognitive impairment (abMoCA-B = -0.14, 95% CI [-0.27, -0.02]). Similar findings were replicated with plasma markers.
Conclusion:
Amyloid pathology may underlie SFC disruptions, contributing to cognitive decline in AD. These findings suggest that SFC may serve as a potential biomarker for amyloid-related neurodegeneration and cognitive impairment.
Trial Registration:
The SILCODE is listed on the ClinicalTrials.gov registry (SILCODE: NCT03370744).
Related Concept Videos
Amyloid Fibrils
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
Positron Emission Tomography
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body...

